Covis pharma

Photo
10.11.2021 • News

AstraZeneca Sells COPD Drug Rights to Covis

AstraZeneca has agreed to transfer its global rights to two drugs for treating patients with chronic obstructive pulmonary disease (COPD) to Switzerland’s Covis Pharma for $270 million. The transaction is expected to close in the fourth quarter of 2021.

Photo
12.10.2020 • News

Covis Buys US Biotech Amag Pharmaceuticals

Specialty pharma company Covis has agreed to buy US-based Amag Pharmaceuticals, boosting its portfolio of therapies for life-threatening conditions and chronic illnesses.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.